☰

BioLamina AB

Scale laminin production without losing consistency

Industry
Biotechnology (cell culture substrates)
Headquarters
Sundbyberg, Stockholm, Sweden
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of BioLamina AB's published strategy and is not endorsed by, or produced in cooperation with, BioLamina AB. Company website

Strategic priorities

BioLamina makes full-length human recombinant laminins (Biolaminin) — the cell culture substrates that regenerative medicine developers grow stem cells on. Demand for its Cell Therapy Grade reagents has risen sharply, and the company is expanding its Stockholm manufacturing footprint roughly fourfold, including a 340 square metre cleanroom built with QleanAir, with temporary extra capacity at the Testa Center in Uppsala.

The company is venture-backed — around 27 to 29 million US dollars raised to date, including an 18.2 million dollar Series B led by Lauxera Capital Partners in September 2023 — and is opening a commercial office in the Boston area to support US-based cell therapy developers. That puts two things on the same timeline: growing production capacity, and meeting the data-integrity and traceability expectations of FDA CBER (Center for Biologics Evaluation and Research) and EMA as its products move toward clinical grade.

The common thread across all of it is reading process and quality data outside the equipment that produced it. Moving stem cell production from 2D lab plates to 3D stirred-tank bioreactors introduces variables — shear stress, oxygen transfer, local pH — that are hard to hold steady at volume, and the new cleanroom adds a second stream of environmental data. Bringing those together, live, is what lets a small team run a much larger operation with the same product consistency.

Challenges we see

  • Operations Manufacturing

    Holding product consistency as bioreactors move to 3D

    BioLamina is scaling stem cell production from 2D lab plates to 3D industrial bioreactors such as stirred-tank systems. The CEO has publicly described this as the company's central manufacturing hurdle, where product consistency has to be maintained under variable shear stress, oxygen transfer and pH.

    In a 3D reactor the conditions a cell experiences vary across the vessel in ways they do not on a flat plate, so the practical expectation is shifting from checking a batch after it runs to reading process signals against the batch while it is still in the reactor.

  • Digital Integration

    Reading cleanroom and bioprocess data together

    The new QleanAir cleanroom produces environmental data — particle counts, humidity, pressure — on its own systems, separate from the bioreactor process data. BioLamina has referred to wanting a single 'Golden Batch' context across the production floor.

    When the environmental record and the process record sit in separate systems, connecting an environmental event to a specific batch outcome is a manual correlation exercise; holding them against one shared batch context makes that link a query rather than an investigation.

  • Operations Manufacturing

    Capturing biological KPIs as data rather than spreadsheets

    Biological KPIs such as Viable Cell Density and growth rate are calculated in Excel, separate from the live process trends. Manual handling of stem cell cultures is a recognised source of run-to-run variation in cell therapy manufacturing.

    Where a KPI is recomputed by hand after each run, the number arrives after the decision it could have informed; capturing it as data at the instrument puts the same figure in front of an operator during the run.

  • Compliance Regulatory

    Producing regulator-ready evidence as products move to clinical grade

    As BioLamina moves toward Cell Therapy Grade products, FDA CBER and EMA expectations on data integrity and traceability rise. Today audit readiness is assembled largely by compiling records by hand for each submission.

    As more of the portfolio becomes clinical grade, the evidence chain from raw material to certificate of analysis has to be reproducible on demand, which favours records generated by systems over records compiled for a submission.

  • Digital Operations

    Working across the Sweden and US sites as one operation

    With the Boston commercial office added to the Sundbyberg headquarters and the Uppsala expansion capacity, teams describe wanting boundaryless day-to-day work across locations.

    Two small sites working from the same research and process data need that data to be reachable and consistent from both, so infrastructure resilience — rather than the science — sets whether the second site can work from the same picture.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Reading bioreactor process signals while the batch runs

    Scaling stem cell production into 3D stirred-tank bioreactors introduces variables — shear stress, oxygen transfer, local pH — that current systems largely review after a run rather than during it. The CEO has named this as the company's central scale-up hurdle.

    Instrumenting the reactors and streaming process data into a monitored model lets a deviation be flagged against the batch that is still in the vessel, and gives the same live view of the process to operators and process scientists at once.

    • The company's CEO, on scaling stem cell production to industrial bioreactors, GeneOnline, 2024
    • BioLamina, large-scale cell production application note, 2022

  2. Putting cleanroom and bioprocess data on one shared context

    The 340 square metre QleanAir cleanroom reports particle, humidity and pressure data on its own systems, disconnected from the bioreactor process data, so an environmental event and a batch outcome live in two places.

    A single-site data layer that loads cleanroom OT data and bioprocess data against one batch context lets an environmental event be read against the batch it affected, and supports condition-based maintenance before a cleanroom fault reaches a run.

    • BioLamina press release on the QleanAir cleanroom facility, 2022
    • BioLamina AB facility expansion announcement

  3. Calculating biological KPIs in the platform instead of Excel

    Viable Cell Density, growth rate and related KPIs are calculated in Excel, off to the side of the live process trends, so the figure that could steer a run arrives after it.

    Computing these metrics directly from the process data and showing them live moves the operator from a spreadsheet read afterwards to a reading during the run, and removes a manual re-keying step from every batch.

    • Cell X Technologies and BioLamina collaboration announcement, PR Newswire, 2025

  4. Assembling regulatory and quality documentation from source records

    As products move to Cell Therapy Grade, certificates of analysis, batch documentation and audit packages are compiled by hand for each submission, which for a small team competes directly with the technical work.

    Narrow, reviewable agents can draft a certificate of analysis or batch summary from the underlying records and check it against its template before review, with a named person approving each output, so the compilation step shrinks without loosening the evidence.

    • BioLamina, on the move to Cell Therapy Grade products and GMP-compliant workflows

  5. Making research data reachable from both Sweden and Boston

    The Boston commercial office and the Sundbyberg headquarters need to work from the same research and process data, and the current infrastructure was built for a single-site operation.

    Decoupling the lab software from the specific hardware it runs on lets research and process data be reached consistently from both locations with built-in redundancy, so a hardware fault at one site does not stop work at the other.

    • BioLamina newsroom, opening of the Boston office
    • BioLamina AB sets the stage for US expansion

What we'd propose

  • Digital Lab

    Live bioreactor process monitoring for scale-up

    We instrument the bioreactors and bring their process data into one monitored time-series model, so a deviation is flagged against the batch currently in the vessel rather than found in a report afterward — the direct answer to the CEO's stated scale-up hurdle.

    • Reactor data acquisition

      Getting data off the equipment

      Connect the reactors, pumps and sensors through OPC UA (Open Platform Communications Unified Architecture) or MQTT so process values leave the equipment in a documented, vendor-neutral form instead of staying inside a single controller.

    • Deviation detection against the running batch

      A signal during the run

      Build the normal operating envelope for each critical parameter from past runs, then flag drift against the current batch, so an operator sees a signal in minutes rather than a result in a later analysis.

    • Golden-batch overlay

      Compare against the best run

      Overlay the current run against a stored reference profile so a deviation from the pattern of a known-good batch is visible while there is still time to act on it.

    • Deviations surface against the batch in the vessel, not the batch that already finished.
    • Operators and process scientists work from the same live view instead of separate extracts.
    • The reference profile makes scale-up decisions a comparison against a known-good run rather than a judgement in isolation.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    One data context for cleanroom and bioprocess

    A single-site data layer, scoped to the expanded Stockholm facility, that loads QleanAir cleanroom environmental data and bioreactor process data against one batch context, so an environmental event and a batch outcome can be read together.

    • Cleanroom-to-bioprocess data bridge

      One batch context

      Bring QleanAir cleanroom data — particle counts, humidity, pressure — and bioreactor process data into one model keyed to the batch, using OPC UA at the boundary so records arrive in a documented form.

    • Condition-based maintenance signals

      Catch faults before the batch does

      Watch the cleanroom's fan filter and interlock systems for drift so a component is flagged for attention before a fault reaches a production run, rather than after a batch is affected.

    • Root-cause queries across the two streams

      Environment linked to outcome

      Store the environmental and process records against the same batch so an operator can trace a batch outcome back to the conditions it ran under as a query, not a manual reconciliation.

    • An environmental event can be read against the specific batch it touched.
    • Cleanroom faults are caught as drift rather than as a compromised batch.
    • The data layer is sized to one growing site, not a multi-plant programme the company does not need yet.

    We've done this before

    See how we do Enterprise AI
  • Agents

    Certificate-of-analysis and quality document agents

    Narrow, reviewable agents that take the repetitive part of quality documentation: drafting a certificate of analysis or batch summary from the underlying records and checking it against its template before review. A named person approves every output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a certificate of analysis or batch summary directly from the process and quality records, so a scientist edits and judges rather than compiles from scratch.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its template and the site's checklist, returning missing or inconsistent sections before it enters the human review queue.

    • Traceable evidence trail

      Every figure back to its source

      Keep each value in a generated document linked to the record it came from, so an auditor can follow a certificate back to the run that produced each number.

    • The compilation step shrinks without loosening the evidence behind it.
    • Documents reach review already complete, so the queue moves faster for a small team.
    • Each figure in a certificate is traceable to the record it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents
  • Digital Lab

    Resilient research infrastructure across two sites

    A cluster environment that decouples BioLamina's lab software from the specific hardware it runs on, so research and process data is reachable and consistent from both Sundbyberg and Boston, with built-in redundancy — sized for two small sites, not a global data centre.

    • Software decoupled from hardware

      Workloads that can move

      Package lab applications so they can run on more than one node and move between them, so a hardware fault does not take an application offline with it.

    • Consistent access from both sites

      Same data, Sweden and Boston

      Set up the data links so both the Sundbyberg and Boston teams work from the same research and process data, rather than each keeping its own copy.

    • Built-in redundancy

      One node can fail

      Run with enough spare capacity that a single node failure does not interrupt ongoing work, which matters most when the two teams are in different time zones.

    • Both sites work from the same data instead of divergent local copies.
    • A hardware fault at one site does not stop work at the other.
    • The setup is scaled to two offices, so it is something a company this size can actually run.

    We've done this before

    See how we do Digital Lab

Where QB Systems fits

Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.

Applications
Bioreactors

Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.

Deployment
Retrofit

Existing equipment keeps running; QB takes over the PLC, or reads from it without touching control.

Scale
Benchtop (1–8 L)

Glass vessels with the complete hardware and software stack. This is the core range for development work.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what BioLamina AB's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Bioreactor process data 35 → 82
Product consistency in scale-up is confirmed largely by reviewing runs after the fact rather than by continuous monitoring in the vessel, which is consistent with the CEO's description of the 3D scale-up as the central hurdle.
Cleanroom-bioprocess integration 30 → 80
The new QleanAir cleanroom reports environmental data on its own systems, separate from bioreactor process data, so a single Golden Batch context is ahead of the company rather than in place.
KPIs as data 38 → 78
Biological KPIs such as Viable Cell Density are calculated in Excel alongside, rather than inside, the live process trends, which favours capturing them at the instrument.
Regulatory traceability 45 → 85
The move to Cell Therapy Grade raises FDA CBER and EMA expectations on data integrity, and audit readiness is assembled by hand today rather than generated by systems.
Cross-site infrastructure 42 → 76
Infrastructure built for a single Swedish site now supports a two-site operation with the Boston office, so resilience and consistent access across locations become the constraint rather than the science.
Automation and repeatability 40 → 80
The Cell X Technologies collaboration signals a move toward more automated, less operator-dependent handling, which the underlying data flow needs to keep pace with.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with BioLamina AB, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].